Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel ...
Presentations to Include Long-term Safety and Efficacy Data from the ATLAS Trial Extension Study of AP01 (Inhaled Pirfenidone) for Pulmonary Fibrosis Avalyn to be featured in ATS Mini Theater Program and Respiratory Innovation Summit CAMBRIDGE, Mass., May …